Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs

Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs  Australia-based Phase 2a clinical study to evaluate broad-spectrum influenza vaccine candidate, OVX836 in combination with Quadrivalent Influenza Vaccines (QIVs) An enrollment of over 500 participants across Australia is anticipated  Lyon, France – June 15, 2023 – Osivax, a biopharmaceutical company developing …

Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine

Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine A Bill & Melinda Gates Foundation grant will be used to expand research and development of OVX836 in a wide range of seasonal and highly pathogenic influenza strains  Osivax continues evaluating OVX836 across several phase 2 clinical trials in healthy volunteers …